- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
According to our latest study, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was valued at USD 3425.9 million in 2022 and is forecast to a readjusted size of USD 4258.9 million by 2029 with a CAGR of 3.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report is a detailed and comprehensive analysis for global Benign Prostatic Hyperplasia (BPH) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2018-2029
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2018-2029
Global Benign Prostatic Hyperplasia (BPH) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2018-2029
Global Benign Prostatic Hyperplasia (BPH) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Benign Prostatic Hyperplasia (BPH) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Benign Prostatic Hyperplasia (BPH) Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Market segment by Application
Hospitals
Drugstores
Others
Major players covered
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Drugs from 2018 to 2023.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia (BPH) Drugs.
Chapter 14 and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Alpha-Blocker
1.3.3 Phosphodiesterase Type-5 Inhibitors
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Drugstores
1.4.4 Others
1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size & Forecast
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (2018-2029)
1.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Eli Lilly Recent Developments/Updates
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GlaxoSmithKline Recent Developments/Updates
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Astellas Pharma Recent Developments/Updates
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi Recent Developments/Updates
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Recent Developments/Updates
2.6 Abbott
2.6.1 Abbott Details
2.6.2 Abbott Major Business
2.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Abbott Recent Developments/Updates
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Allergan Recent Developments/Updates
2.8 TEVA
2.8.1 TEVA Details
2.8.2 TEVA Major Business
2.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 TEVA Recent Developments/Updates
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Mylan Recent Developments/Updates
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Novartis Recent Developments/Updates
2.11 Merck
2.11.1 Merck Details
2.11.2 Merck Major Business
2.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Merck Recent Developments/Updates
3 Competitive Environment: Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2022
3.5 Benign Prostatic Hyperplasia (BPH) Drugs Market: Overall Company Footprint Analysis
3.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market: Region Footprint
3.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Type Footprint
3.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Region (2018-2029)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type (2018-2029)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application (2018-2029)
6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Application (2018-2029)
7 North America
7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
7.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
7.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
8.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
9.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
10.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
10.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
10.3.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
11.3.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Benign Prostatic Hyperplasia (BPH) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Benign Prostatic Hyperplasia (BPH) Drugs
13.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Process
13.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Benign Prostatic Hyperplasia (BPH) Drugs Typical Distributors
14.3 Benign Prostatic Hyperplasia (BPH) Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 6. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Eli Lilly Recent Developments/Updates
Table 8. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 9. GlaxoSmithKline Major Business
Table 10. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 11. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. GlaxoSmithKline Recent Developments/Updates
Table 13. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 14. Astellas Pharma Major Business
Table 15. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 16. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Astellas Pharma Recent Developments/Updates
Table 18. Sanofi Basic Information, Manufacturing Base and Competitors
Table 19. Sanofi Major Business
Table 20. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 21. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Sanofi Recent Developments/Updates
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 26. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Pfizer Recent Developments/Updates
Table 28. Abbott Basic Information, Manufacturing Base and Competitors
Table 29. Abbott Major Business
Table 30. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 31. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Abbott Recent Developments/Updates
Table 33. Allergan Basic Information, Manufacturing Base and Competitors
Table 34. Allergan Major Business
Table 35. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 36. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Allergan Recent Developments/Updates
Table 38. TEVA Basic Information, Manufacturing Base and Competitors
Table 39. TEVA Major Business
Table 40. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 41. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. TEVA Recent Developments/Updates
Table 43. Mylan Basic Information, Manufacturing Base and Competitors
Table 44. Mylan Major Business
Table 45. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 46. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Mylan Recent Developments/Updates
Table 48. Novartis Basic Information, Manufacturing Base and Competitors
Table 49. Novartis Major Business
Table 50. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 51. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Novartis Recent Developments/Updates
Table 53. Merck Basic Information, Manufacturing Base and Competitors
Table 54. Merck Major Business
Table 55. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 56. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (M Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Merck Recent Developments/Updates
Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Manufacturer (2018-2023) & (M Units)
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 61. Market Position of Manufacturers in Benign Prostatic Hyperplasia (BPH) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 62. Head Office and Benign Prostatic Hyperplasia (BPH) Drugs Production Site of Key Manufacturer
Table 63. Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Type Footprint
Table 64. Benign Prostatic Hyperplasia (BPH) Drugs Market: Company Product Application Footprint
Table 65. Benign Prostatic Hyperplasia (BPH) Drugs New Market Entrants and Barriers to Market Entry
Table 66. Benign Prostatic Hyperplasia (BPH) Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2018-2023) & (M Units)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2024-2029) & (M Units)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 70. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 71. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 72. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 73. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 74. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 75. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 83. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 84. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 85. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 86. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 87. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 88. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 89. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2023) & (M Units)
Table 90. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2024-2029) & (M Units)
Table 91. North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 92. North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 94. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 95. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 96. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 97. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2023) & (M Units)
Table 98. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2024-2029) & (M Units)
Table 99. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 102. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 103. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 104. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 105. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2018-2023) & (M Units)
Table 106. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2024-2029) & (M Units)
Table 107. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 108. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 109. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 110. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 111. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 112. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 113. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2018-2023) & (M Units)
Table 114. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Country (2024-2029) & (M Units)
Table 115. South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 116. South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 117. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2018-2023) & (M Units)
Table 118. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Type (2024-2029) & (M Units)
Table 119. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2018-2023) & (M Units)
Table 120. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Application (2024-2029) & (M Units)
Table 121. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2018-2023) & (M Units)
Table 122. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity by Region (2024-2029) & (M Units)
Table 123. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 124. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 125. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material
Table 126. Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials
Table 127. Benign Prostatic Hyperplasia (BPH) Drugs Typical Distributors
Table 128. Benign Prostatic Hyperplasia (BPH) Drugs Typical Customers
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Type in 2022
Figure 4. Alpha-Blocker Examples
Figure 5. Phosphodiesterase Type-5 Inhibitors Examples
Figure 6. Others Examples
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Application in 2022
Figure 9. Hospitals Examples
Figure 10. Drugstores Examples
Figure 11. Others Examples
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity (2018-2029) & (M Units)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Benign Prostatic Hyperplasia (BPH) Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 54. China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Figure 75. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Figure 76. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2022
Figure 79. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 80. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
